Survival Outcomes of a Large Cohort of Acral Melanoma Patients Treated at a South African Referral Hospital

Overview

Journal J Skin Cancer

Publisher Wiley

Specialty Dermatology

Date 2025 Feb 17

PMID 39959567

Authors

Bianca Tod

Tonya Esterhuizen

Willem Visser

Maritha Kotze

Anne Bowcock

Johann Schneider

Henriette Burger

Affiliations

Soon will be listed here.

Abstract

Acral melanoma (AM) is the most common type of melanoma arising in people with skin of color. AM is often diagnosed late and associated with poor outcomes. Melanoma outcomes are also impacted by socioeconomic status. Although uncommon, AM is a public health concern in South Africa because of its epidemiology and association with health access issues, which predispose to late diagnosis. South African patients are managed based on staging systems and treatment guidelines developed for other populations. This cohort study aimed to determine the survival outcomes in a cohort of South African AM patients and how these were associated with demographic, clinical, pathological, and management data. The study included patients diagnosed at a referral hospital between 1 January 2010 and 31 December 2021. Analysis occurred in 2022 and 2023. The main outcomes of interest were survival time in months (overall and progression-free, OS and PFS). Survival outcomes were analyzed using Kaplan-Meier survival curves. Survival probabilities were compared between subgroups using log-rank tests. Univariate and multivariable analyses were performed using the Cox proportional hazards models to assess factors associated with survival. Ninety-one patients were included in the analysis. After a median follow-up of 28 months (range: 0-151 months), 48 patients (52.7%) had died. The 3- and 5-year survival rates for the entire cohort were 64.8% and 56.0% respectively. Notably, the OS and PFS were not affected by the population group ( value = 0.628, not significant). The examination of OS and PFS by the clinical stage group demonstrated proportional hazard. Although SLNB comprised a small group, the results appear to be prognostically valid, specifically for OS. The results indicate that the AJCC eighth edition staging is broadly applicable to AM in this population; however, a rigorous comparison was not possible. SLNB appears to be prognostically valid. No difference in survival outcomes by population group was shown.

References

Lino-Silva L, Dominguez-Rodriguez J, Aguilar-Romero J, Martinez-Said H, Salcedo-Hernandez R, Garcia-Perez L . Melanoma in Mexico: Clinicopathologic Features in a Population with Predominance of Acral Lentiginous Subtype. Ann Surg Oncol. 2016; 23(13):4189-4194. DOI: 10.1245/s10434-016-5394-x. View

Moon K, Choi Y, Kim J, Jin S, Shin M, Shim H . Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features. J Invest Dermatol. 2017; 138(4):933-945. DOI: 10.1016/j.jid.2017.11.017. View

Jung H, Kweon S, Lee J, Lee S, Yun S . A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. JAMA Dermatol. 2013; 149(11):1281-8. DOI: 10.1001/jamadermatol.2013.5853. View

Duarte C, Florez J, Lopez H, Meneses M, de Vries E . Survival of acral lentiginous melanoma in the National Cancer Institute of Colombia. J Eur Acad Dermatol Venereol. 2016; 31(3):438-442. DOI: 10.1111/jdv.13913. View

Merkel E, Gerami P . Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features. Lab Invest. 2017; 97(6):630-635. DOI: 10.1038/labinvest.2016.147. View

Phan A, Touzet S, Dalle S, Ronger-Savle S, Balme B, Thomas L . Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006; 155(3):561-9. DOI: 10.1111/j.1365-2133.2006.07368.x. View

. Genomic Classification of Cutaneous Melanoma. Cell. 2015; 161(7):1681-96. PMC: 4580370. DOI: 10.1016/j.cell.2015.05.044. View

Lim Y, Lee J, Lee D . Is the survival rate for acral melanoma actually worse than other cutaneous melanomas?. J Dermatol. 2020; 47(3):251-256. DOI: 10.1111/1346-8138.15201. View

Boriani F, OLeary F, Tohill M, Orlando A . Acral Lentiginous Melanoma - misdiagnosis, referral delay and 5 years specific survival according to site. Eur Rev Med Pharmacol Sci. 2014; 18(14):1990-6. View

10.

Wada M, Ito T, Tsuji G, Nakahara T, Hagihara A, Furue M . Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. J Dermatol. 2017; 44(8):932-938. DOI: 10.1111/1346-8138.13834. View

11.

Ryu G, Choi Y, Jin S, Chung I, Shin M, Yun S . Volar location and degree of pigmentation are associated with poor survival and first metastasis pattern in acral melanoma. Pigment Cell Melanoma Res. 2021; 34(6):1094-1104. DOI: 10.1111/pcmr.12983. View

12.

Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tuting T . Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2017; 178(2):443-451. DOI: 10.1111/bjd.15803. View

13.

Mahendraraj K, Sidhu K, Lau C, McRoy G, Chamberlain R, Smith F . Malignant Melanoma in African-Americans: A Population-Based Clinical Outcomes Study Involving 1106 African-American Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1988-2011). Medicine (Baltimore). 2017; 96(15):e6258. PMC: 5403065. DOI: 10.1097/MD.0000000000006258. View

14.

Swan M, Hudson D . Malignant melanoma in South Africans of mixed ancestry: a retrospective analysis. Melanoma Res. 2003; 13(4):415-9. DOI: 10.1097/00008390-200308000-00012. View

14.

Bozek K, Khrameeva E, Reznick J, Omerbasic D, Bennett N, Lewin G . Lipidome determinants of maximal lifespan in mammals. Sci Rep. 2017; 7(1):5. PMC: 5428381. DOI: 10.1038/s41598-017-00037-7. View

15.

Okunola A, Baatjes K, Zemlin A, Torrorey-Sawe R, Conradie M, Kidd M . Pathology-supported genetic testing for the application of breast cancer pharmacodiagnostics: family counselling, lifestyle adjustments and change of medication. Expert Rev Mol Diagn. 2023; 23(5):431-443. DOI: 10.1080/14737159.2023.2203815. View

16.

Tas F, Erturk K . Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival. Pathobiology. 2018; 85(4):227-231. DOI: 10.1159/000488457. View

17.

Lv J, Dai B, Kong Y, Shen X, Kong J . Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases. Sci Rep. 2016; 6:31432. PMC: 4992860. DOI: 10.1038/srep31432. View

18.

Sheen Y, Liao Y, Lin M, Chen J, Liau J, Tseng Y . A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress. Sci Rep. 2017; 7(1):5564. PMC: 5514126. DOI: 10.1038/s41598-017-05809-9. View

19.

Bello D, Chou J, Panageas K, Brady M, Coit D, Carvajal R . Prognosis of acral melanoma: a series of 281 patients. Ann Surg Oncol. 2013; 20(11):3618-25. DOI: 10.1245/s10434-013-3089-0. View